In preclinical tendon research, BPC-157 has become the most studied research peptide. Preclinical studies based on animals suggest that BPC-157 interacts with multiple biological pathways involved in the organization of tendon, fibroblast activity, remodeling of collagen, formation of new blood vessels (angiogenesis), and nitric oxide signaling. Although these findings are promising, a big portion of them comes from in vitro studies and rodent models with no clinical trials based on humans. (PubMed Central)
Summary
| Research Field | Results of Published Studies |
| Healing of Tendon | Improved structural organization in animal models |
| Activity of Fibroblast | Enhanced proliferation and migration of cells |
| Remodeling of collagen | Improved alignment of collagen in preclinical models |
| Angiogenesis | Activation of vascular signaling pathways |
| Growth hormone receptor | In tendon fibroblasts, increased receptor expression is noted |
| Current evidence | Primarily preclinical with limited human data |
Tendon Research and BPC-157: An Overview
Tendon injuries are among the most challenging musculoskeletal conditions to investigate due to the relatively poor blood supply to tendons and their slow healing in experimental models. Researchers have been searching for compounds for decades to better understand tendon biology and tissue repair.
So, a peptide that continues to draw scientific interest is BPC-157. Early in the 1990s, the research group headed by Predrag Sikirić isolated BPC-157 from human gastric juice, and it has been the subject of many laboratory studies involving tendons, ligaments, muscles, vascular tissue, and connective tissue. (PubMed Central)
Much of the evidence being published today comes from controlled animal experiments and cellular studies, not human clinical trials.
Why are Tendon Models Important in Research?
The mechanism of tendons is really simple. Healthy tendons allow normal movement by transferring force from muscles to bones. It has a dense collagen structure, which gives it strength and power, but this density also limits its blood supply. That is why tendon injuries are not easy to study, and healing processes can be slow in experimental settings.
Tendon models are used by researchers to investigate several biological questions, including:
- Organization of collagen
- fibroblast behavior
- Formation of blood vessels
- inflammatory signaling
- biomechanical strength
These models provide important information about the behaviour of connective tissues under controlled laboratory conditions.
How BPC-157 Became a Research Focus For Tendons
The interest in BPC-157 came after initial animal studies demonstrated changes in tendon repair after experimental injury. Models of Achilles tendon transection, tendon detachment studies, and cultured tendon fibroblasts began to be studied in the 2000s.
Recent narrative and systematic reviews have consistently investigated the interaction of BPC-157 with tendon fibroblasts, collagen fibers, vascular signaling, and the organization of connective tissue. Several published studies also investigated its effects in conditions that typically impair tendon repair, such as reduced blood supply and corticosteroid exposure. (PubMed Central) These studies have helped BPC-157 to become one of the most studied peptides in preclinical tendon studies.
Early Published Studies’ Results
The first tendon investigations were primarily concentrated on structural healing.
In experimental models of tendons treated with BPC-157, researchers observed more organized collagen fibers and improved tendon architecture when compared to untreated controls. Further laboratory work reported increased fibroblast activity, which is important as fibroblasts are responsible for producing collagen and maintaining tendon structure. (PubMed Central)
Another interesting observation was in the studies of the expression of growth hormone receptors. Researchers reported another pathway that needs to be explored further, and that is increased growth hormone receptor activity in tendon fibroblasts exposed to BPC-157. These results are still confined to laboratory research and have not yet been confirmed in human clinical studies. (PubMed Central)
Molecular Mechanisms Identified in Tendon Models
One of the most exciting questions about BPC-157 is how exactly the peptide interacts with tendons in a research setting. Over the past 20 years, researchers have come up with some interesting ideas for how it works based on lab and animal work. These mechanisms are still under investigation, and few have appeared consistently in published research.
Angiogenesis and Blood Vessel Formation
Healthy blood flow is essential for tendon repair, as tendons naturally get a limited blood supply. Studies show BPC-157 interacts with angiogenesis pathways—particularly VEGFR2 and the Akt-eNOS signalling pathway. These pathways control the formation of new blood vessels. They also help in supporting oxygen and nutrient delivery to injured tissue in laboratory models. (PubMed Central)
Scientists think this vascular reaction might partially be responsible for BPC’s continued interest in tendon biology studies.
Fibroblast Activity and Collagen Organization
Fibroblasts are the essential cells responsible for manufacturing collagen, which lends tendons their strength and structure. Research has found that BPC-157 can increase fibroblast migration and affect the organization of collagen during the repair of tendons in a research setting. This was demonstrated in both Achilles tendon models and other types of connective tissues (PubMed Central)
Rather than actually making new tendon tissue itself, evidence points to BPC-157 potentially changing the conditions that tendon cells use to arrange and remodel collagen.
Growth Hormone Receptor Expression
One of the most interesting mechanistic studies looked at tendon fibroblasts, cells isolated from rat Achilles tendons.
The researchers found that BPC-157 increased the growth hormone receptor (GHR) expression in those fibroblasts. When they added growth hormone after that, the fibroblast proliferation went up through stimulation of the Janus kinase 2 (JAK2) signalling pathway. These findings suggest that BPC-157 might increase the sensitivity of tendon fibroblasts to growth hormones in the lab, rather than working as a growth hormone itself. (PubMed)
While exciting, this mechanism is still unproven outside of the lab.
FAK-Paxillin Signaling
More recently, other researchers have pointed to a different pathway, i.e FAK-paxillin.
This pathway assists cells in attaching to surrounding tissues, migrating towards an injury site, and organizing collagen fibers during tissue remodeling. As per recent narrative reviews, activation of FAK-paxillin might also help explain the better tendon architecture observed in some animal-based studies. (PubMed Central)
What Recent Reviews Conclude
Recent literature reviews in 2025 and 2026 reviewed dozens of experimental studies on BPC-157 and musculoskeletal tissues.
Across these reviews, several observations appear consistently:
- Tendon organization improved in many rodent models.
- Fibroblast migration and collagen alignment were frequently enhanced.
- Biomechanical measures, including load-to-failure and stiffness, improved in several tendon injury experiments.
- Angiogenesis and endothelial signalling were repeatedly implicated as important.
- Growth hormone receptor expression was another explanation of the peptide’s action on tendon fibroblasts. (PubMed Central)
While these findings are promising, the authors also pointed out that we still have weak evidence, as most studies involved either rodents or cells, not people. (PubMed)
Current Limitations of the Evidence
The growing number of publications has expanded scientific understanding of BPC-157, but important limitations remain.
First, nearly all tendon studies have been conducted in rats, mice, or laboratory cell cultures. Animal models provide valuable mechanistic insights, but they cannot fully predict how a compound will behave in humans.
Second, experimental designs vary considerably. Researchers use different injury models, treatment protocols, observation periods, and outcome measures. This variability makes direct comparisons difficult.
Third, large randomized human clinical trials evaluating BPC-157 for tendon-related conditions are still lacking. Recent reviews consistently conclude that more high-quality clinical research is needed before findings from preclinical models can be translated into clinical practice. (PubMed)
FAQs
1. What are the results of tendon studies about BPC-157?
Published animal and laboratory studies have reported changes in collagen organization, fibroblast activity, angiogenesis, and biomechanical properties during tendon repair. Most of these findings come from preclinical models. (PubMed Central)
2. Does BPC-157 improve tendon healing in humans?
There is currently insufficient high-quality clinical evidence to confirm similar findings in humans. Most published research has been conducted in animals or laboratory settings.
3. Why do researchers study fibroblasts?
Fibroblasts produce collagen and maintain tendon structure. Understanding how these cells respond helps researchers investigate tendon biology and tissue remodeling.
4. What makes BPC-157 different from other research peptides?
Unlike many investigational peptides that target a single signaling pathway, BPC-157 has been studied across several interconnected mechanisms, including angiogenesis, nitric oxide signaling, fibroblast migration, and growth hormone receptor expression. These observations remain under investigation in preclinical models. (PubMed Central)
Concluding Remarks
Over the last 30 years, BPC-157 has been one of the most studied peptides when it comes to tendon research. Studies show it interacts with various biological systems involved in tendon remodelling, such as collagen organisation, fibroblasts, angiogenesis, and cellular signalling.
Even so, all the existing evidence is mainly from animal studies and lab research. Recent reviews agree that these are fascinating results, but these findings should be understood carefully until we have some large human clinical studies. Until then, we hope more research will shed light on BPC-157’s mechanisms and its place in musculoskeletal science. (PubMed)
References
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (2025). PMC.
- Sikirić P, et al. Stable Gastric Pentadecapeptide BPC-157: Review of Experimental Findings (2010).
- Chang CH, Tsai WC, et al. Pentadecapeptide BPC-157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts (2014).
- Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157—A Review (2026).
Research Use Only Disclaimer
BPC-157 is an investigational peptide meant only for lab use. It’s not approved by the FDA for human use or for the diagnosis, treatment, prevention, or cure of any disease. All results mentioned in this article are based on preclinical and lab studies and don’t indicate any clinical benefits for people.
